NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
1. NextCure has initiated Phase 1 study for LNCB74 treating multiple cancers. 2. FDA approved LNCB74's Investigational New Drug application in December 2024. 3. LNCB74 aims to improve treatment options for cancer patients unresponsive to current therapies.